Will the mRNA Flu Shot Work Better Than a Regular Seasonal One? What the Science Says

The US FDA granted approval to Moderna’s mRNA-based flu vaccine, mFLUSIVA, for adults aged 50–64, and accelerated approval for adults aged 65 and older.